Implications of Hypertrophic Cardiomyopathy Transmitted by Sperm Donation

Barry J. Maron, MD
John R. Lesser, MD
Nelson B. Schiller, MD
Kevin M. Harris, MD
Colleen Brown, ScM
Heidi L. Rehm, PhD

Donation of Sperm to achieve pregnancy, either in the absence of a male partner or when a fertility problem exists, is practiced with considerable frequency.1,2 Sperm banks, Internet-based agencies, or private agreements have evolved over the past 25 years as mechanisms for interfacing potential recipient women with suitable donors. The donor thereby becomes the genetic and biological father of each child produced with his sperm. While the US Food and Drug Administration (FDA) inspects the operation of the banks and screening procedures for donors,1,2 this process has been directed primarily toward the prevention of infectious diseases, with little attention to the potential transmission of genetic diseases.1,2

We report a novel circumstance in which sperm donated by a man with unrecognized hypertrophic cardiomyopathy (HCM)3 produced several affected children including some at increased risk for premature cardiac death.

CASE REPORT

Donor

A 23-year-old white man (III-3, Figure 1) in good health, and asymptomatic, with no history of cardiac disease, donated his sperm on multiple occasions (n=95) over a 2-year period in 1990-1991 under a contractual agreement with one of the 110 US sperm banks. He was screened by a comprehensive personal and family history, physical examination, and by laboratory testing for infectious and transmittable diseases: human immunodeficiency virus 1 and human immunodeficiency virus 2, human T-lymphotropic virus 1 and human T-lymphotropic virus 2, syphilis, cytomegalovirus, hepatitis B and C, gonorrhea and chlamydia, as well as Tay-Sachs disease.

Several years later an offspring was diagnosed with HCM, which triggered the notification to all known recipients of this donor’s sperm that several years earlier had been donated. The donor thereby became aware of the genetic effects of his sperm.

Context

Sperm donation is an increasingly common practice for achieving pregnancy in the absence of a male partner or when fertility is problematic. The unintended consequence in which genetic diseases are unwittingly transmitted to offspring is an underrecognized public health issue not previously prioritized by US Food and Drug Administration guidelines.

Objective

To report the clinical circumstances and implication of hypertrophic cardiomyopathy (HCM) transmitted by sperm donation to recipients.

Setting

Voluntary sperm donation through a US Food and Drug Administration–approved tissue bank.

Main Outcome Measure

Incidence of genetically affected offspring and clinical outcomes to date.

Results

An asymptomatic 23-year-old man who had no personal knowledge of underlying heart disease and who underwent standard testing that was negative for infectious diseases, repeatedly donated sperm over a 2-year period (1990-1991). The donor was later shown to be affected (in 2005) by a novel β-myosin heavy-chain mutation that caused HCM, after an offspring was clinically diagnosed with this disease. Of the 24 children known to be offspring of the donor, including 22 who were products of fertilization via sperm donation and 2 conceived by the donor’s wife, a total of 9 genetically affected offspring, 2 to 16 years of age and 6 males, have been identified with HCM (2005-2009). Three of the 9 gene-positive children have currently expressed phenotypic evidence of HCM, including one who died at age 2 years due to progressive and unremitting heart failure with marked hypertrophy, and also 2 survivors with extreme left ventricular hypertrophy at age 15 years. The latter 2 children and the donor are judged likely to be at increased risk for sudden death.

Conclusions

This case series underscores the potential risk for transmission of inherited cardiovascular diseases through voluntary sperm donation, a problem largely unappreciated by the medical community and agencies regulating tissue donation. Recommendations include improved screening guidelines for donors to exclude cardiovascular diseases (eg, HCM) such as consideration for 12-lead electrocardiograms.

Author Affiliations: Hypertrophic Cardiomyopathy Center, Minneapolis Heart Institute Foundation and Abbott Northwestern Hospital, Minneapolis, Minnesota (Drs Maron, Lesser, and Harris); Partners Health care Center for Personalized Genetic Medicine, Department of Pathology, Brigham and Women’s Hospital, and Harvard Medical School, Boston, Massachusetts (Dr Rehm); and Divisions of Cardiology and Medical Genetics, University of California at San Francisco, San Francisco (Dr Schiller and Ms Brown).

Corresponding Author: Barry J. Maron, MD, Minneapolis Heart Institute Foundation, 920 E 28th St, Ste 620, Minneapolis, MN 55407 (hcm.maron@mnhif.org).
an inherited form of heart disease could have been transmitted to their children. Genetic testing was offered first to the donor and later to the offspring.

IRB approval and protocols for this study were provided through Brigham and Women’s Hospital, Boston, Massachusetts, and Abbott-Northwestern Hospital.

**Genetic Studies**

At the Laboratory for Molecular Medicine, Partners Healthcare Center for Personalized Genetic Medicine, DNA from the donor was tested for mutations in 5 genes (MYBPC3, MYH7, TNNT2, TNNI3, and TPM1). A novel β-myosin heavy-chain (MYH7) missense mutation, Arg169Gly (505A>G), was located at a highly conserved residue in the myosin motor domain.

Twenty-two children (among at least 13 families) are known to have been products of fertilization via sperm donation. Of these, 16 have been tested for the Arg169Gly mutation, and 8 were positive (Figure 1). Eight other offspring have tested negative, aged 9 to 15 years (mean age, 12.5 years; 4 males).

The donor (III-3, Figure 1) also had 2 children conceived with his wife; one of these children tested positive.

Several factors support a pathogenic role for the Arg169Gly mutation including the absence of the variant in more than 3000 chromosomes tested, the high conservation of the Arg169 residue, the location within the motor domain of the β-myosin heavy-chain protein, and consistent segregation of the mutation with the affected offspring.

**Clinical Findings**

Of the 9 children who were mutation-positive (aged 2-16 years; 6 males), one has functional limitation with exertional chest pain and fatigue (IV-4), one experienced presyncope and palpitations (IV-8), and the other 7 remain asymptomatic. Two of the living offspring (IV-4 and IV-8; both with symptoms) have phenotypic evidence of HCM with left ventricular (LV) hypertrophy as assessed by 2-dimensional echocardiography and LV outflow at rest (Figure 1), are 15 years old, and show extreme LV wall thickness involving the ventricular septum of 30 mm and 34 mm (Figure 2).

One of these children (IV-4) has received a prophylactically implanted cardioverter-defibrillator for prevention of sudden death. Another genetically affected offspring, (IV-11, Figure 1) died at 2.5 years of age of obstructive HCM (ventricular septal thickness, 22 mm) and progressive heart failure while awaiting transplant.

Six of the 9 genetically affected children do not currently show LV hypertrophy as assessed by 2-dimensional echocardiography at ages 7, 7, 11, 15, 15, and 16 years (mean age, 12 years), although other findings were consistent with phenotypic expression, including mild systolic motion of the mitral valve in one (IV-6) and an abnormal electrocardiogram in the other (IV-3).

The donor (III-3) demonstrated segmental LV hypertrophy (thickness, 18 mm) confined to the posterior (inferior) LV, a region not reliably detected by echocardiography and

---

**Figure 1. Pedigree Showing Offspring of the Sperm Donor**

In the 2 genetically affected offspring without left ventricular (LV) hypertrophy, other clinical evidence of the hypertrophic cardiomyopathy (HCM) phenotype was present, including abnormal electrocardiogram with T-wave inversion in leads II and III, aVF, and Q waves in leads V1 to V6 (IV-3), or mild systolic anterior motion of the mitral valve (IV-6). One offspring (IV-11) died of progressive heart failure due to obstructive HCM and was tested retrospectively on a stored DNA sample extracted from peripheral blood obtained prior to death. Although cardiac evaluation was not available in any of the donor’s parents, grandparents, or siblings, the donor reported that he was unaware of any evidence of HCM in these family members. The cause of death in the paternal grandmother (I-2) was reported to be a “heart attack” at age 56 years. Both of the donor’s parents underwent prosthetic valve replacement. All offspring with unshaded pedigree symbols had reportedly normal cardiac evaluations. Diamond represents 4 additional offspring who did not participate directly in the study but have not pursued genetic testing and have had ongoing cardiac evaluations that were reportedly normal.
recognized in this patient only by cardiovascular magnetic resonance imaging\(^8\) (Figure 2). Also, the electrocardiogram was abnormal with T-wave inversion (most prominent in \(V_4-V_6\)), and left atrial enlargement. Following gadolinium contrast, extensive delayed enhancement consistent with myocardial fibrosis was largely confined to the hypertrophied region of LV. Hypertrophy was absent by echocardiography in each of the 9 offspring with negative genetic testing.

**COMMENT**

This case study underscores several important principles regarding the relation of sperm donation with inherited heart diseases such as HCM, by illustrating the possibility that genetic conditions can be transmitted unwittingly to offspring by this practice. We are aware of only 1 other documented instance in which a genetic disease was transmitted to an offspring by sperm donation\(^9\).

In the present scenario, the donor was young, healthy, had no personal knowledge of underlying heart disease, and the medical history, physical examination, and standard testing prior to sperm donation showed negative results. Indeed, his diagnosis of HCM was made only after phenotypically expressed disease was identified in an offspring.

Since May 2005, the FDA\(^1\) has regulated donor eligibility and sperm banks for compliance with guidelines also offered by the American Society of Reproductive Medicine\(^2\), the American Association of Tissue Banks, and many states. Although the FDA is mandated to ensure the good health status of donors and prevent transmission of disease, its regulations for sperm banks have focused disproportionately on communicable diseases such as human immunodeficiency virus, human T-lymphotropic virus, cytomegalovirus, hepatitis B and C, gonorrhea, syphilis, and chlamydia (tested every 3 months during the donation period).

Although no accepted guidelines presently exist for the process of noti-
HYPERTROPHIC CARDIOMYOPATHY TRANSMITTED BY SPERM DONATION

Our observations raise considerations for effective screening strategies to prevent donors from propagating mutant genes that cause relatively common genetic diseases such as HCM.

In this regard, it would be impractical to require routine echocardiography as part of noninvasive cardiovascular evaluations, nor is HCM-specific genotyping likely due to its current expense and limited clinical sensitivity. However, given the observations in the donor (12-lead ECG was strikingly abnormal but the echocardiogram was nondiagnostic), as well as recognition that ECGs are abnormal in 80% to 95% of affected HCM adults with LV hypertrophy, it is suggested that the ECG may represent an efficacious strategy for excluding sperm donors with this disease. This approach is reminiscent of that used to detect HCM in large Italian populations of competitive athletes, and also could potentially serve to identify other familial diseases associated with sudden death, such as ion channelopathies (including long QT syndrome).

In conclusion, the novel medical situation reported in this case series raises a largely ignored but potentially significant public health issue, namely the risk for transmission of genetic disease by voluntary gamete donation. There is considerable value in providing the public with information about this issue and raising the possibility of screening strategies for donors to prevent future undesirable propagation of genetic cardiovascular diseases such as HCM.

Author Contributions: Dr Maron had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Study concept and design: Maron, Lesser, Rehm. Acquisition of data: Maron, Lesser, Schiller, Brown, Rehm.

Analysis and interpretation of data: Maron, Lesser, Schiller, Harris, Brown, Rehm.

Drafting of the manuscript: Maron, Lesser, Schiller, Harris, Brown, Rehm. Administrative, technical, or material support: Maron, Lesser, Schiller, Harris, Rehm.

Study supervision: Lesser, Rehm.

Financial Disclosures: Dr Maron reports having a consultant relationship with GeneDx, a subsidiary of Bio-Reference Laboratories (a company that performs genetic testing for hypertrophic cardiomyopathy and other diseases), but reports that he did not have contact with or a relationship to the genetic testing reported in this study. The other authors report no relevant disclosures or associations with industry. Funding/Support: This study was supported in part with a grant from The Hearst Foundations.

Role of the Sponsor: The Hearst Foundations did not participate in the design and conduct of the study; in the collection, analysis, and interpretation of the data; or in the presentation, review, or approval of the manuscript.

Additional Contribution: We thank the donor and the families of the affected offspring for providing permission to publish this information about their cases.

REFERENCES


